Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat ebv negative lymphoma

Molecular Therapy

Volumn 19, Issue 12, 2011, Pages 2258-2268

  Gerdemann, Ulrike ^a   Katari, Usha ^a   Christin, Anne S ^a   Cruz, Conrad R ^a   Tripic, Tamara ^a   Rousseau, Alexandra ^a   Gottschalk, Stephen M ^a   Savoldo, Barbara ^a   Vera, Juan F ^a   Heslop, Helen E ^a   Brenner, Malcolm K ^a   Bollard, Catherine M ^a   Rooney, Cliona M ^a   Leen, Ann M ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; MELANOMA ANTIGEN 4; NY ESO 1 ANTIGEN; PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA; SURVIVIN; SYNOVIAL SARCOMA X ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; EPSTEIN BARR VIRUS; EX VIVO STUDY; HODGKIN DISEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; REGULATORY T LYMPHOCYTE;

HUMAN HERPESVIRUS 4;

EID: 82955219544     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.167     Document Type: Article

References (49)

1. Bollard, CM, Gottschalk, S, Leen, AM, Weiss, H, Straathof, KC, Carrum, G et al. (2007). Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 110:2838-2845. (Pubitemid 350006936)
2. Heslop, HE, Slobod, KS, Pule, MA, Hale, GA, Rousseau, A, Smith, CA et al. (2010). Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115:925-935.
3. Rosenberg, SA, Spiess, P and Lafreniere, R (1986). A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318-1321. (Pubitemid 16002234)
4. Straathof, KC, Bollard, CM, Popat, U, Huls, MH, Lopez, T, Morriss, MC et al. (2005). Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105:1898-1904. (Pubitemid 40731770)
5. Gulley, ML, Eagan, PA, Quintanilla-Martinez, L, Picado, AL, Smir, BN, Childs, C et al. (1994). Epstein-Barr virus DNA is abundant and monoclonal in the Reed-Sternberg cells of Hodgkin's disease: association with mixed cellularity subtype and Hispanic American ethnicity. Blood 83:1595-1602. (Pubitemid 24081574)
6. Gottschalk, S, Ng, CY, Perez, M, Smith, CA, Sample, C, Brenner, MK et al. (2001). An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 97:835-843. (Pubitemid 32154261)
7. Warren, EH, Fujii, N, Akatsuka, Y, Chaney, CN, Mito, JK, Loeb, KR et al. (2010). Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood 115:3869-3878.
8. Dudley, ME, Wunderlich, J, Nishimura, MI, Yu, D, Yang, JC, Topalian, SL et al. (2001). Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 24:363-373. (Pubitemid 32825868)
9. Lozupone, F, Rivoltini, L, Luciani, F, Venditti, M, Lugini, L, Cova, A et al. (2003). Adoptive transfer of an anti-MART-1 (27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice. Eur J Immunol 33:556-566. (Pubitemid 36267622)
10. Khong, HT, Wang, QJ and Rosenberg, SA (2004). Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother 27:184-190. (Pubitemid 39118082)
11. Yamshchikov, GV, Mullins, DW, Chang, CC, Ogino, T, Thompson, L, Presley, J et al. (2005). Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J Immunol 174:6863-6871. (Pubitemid 40705650)
12. Adida, C, Haioun, C, Gaulard, P, Lepage, E, Morel, P, Briere, J et al. (2000). Prognostic signifcance of survivin expression in diffuse large B-cell lymphomas. Blood 96:1921-1925. (Pubitemid 30661078)
13. Chambost, H, Van Baren, N, Brasseur, F, Godelaine, D, Xerri, L, Landi, SJ et al. (2000). Expression of gene MAGE-A4 in Reed-Sternberg cells. Blood 95:3530-3533. (Pubitemid 30428487)
14. Colleoni, GW, Capodieci, P, Tickoo, S, Cossman, J, Filippa, DA and Ladanyi, M (2002). Expression of SSX genes in the neoplastic cells of Hodgkin's lymphoma. Hum Pathol 33:496-502. (Pubitemid 34747868)
15. Shafer, JA, Cruz, CR, Leen, AM, Ku, S, Lu, A, Rousseau, A et al. (2010). Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma. Leuk Lymphoma 51:870-880.
16. Owaki, T, Asakawa, M, Morishima, N, Hata, K, Fukai, F, Matsui, M et al. (2005). A role for IL-27 in early regulation of Th1 differentiation. J Immunol 175:2191-2200. (Pubitemid 41113825)
17. Giermasz, AS, Urban, JA, Nakamura, Y, Watchmaker, P, Cumberland, RL, Gooding, W et al. (2009). Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. Cancer Immunol Immunother 58:1329-1336.
18. Li, Q, Carr, AL, Donald, EJ, Skitzki, JJ, Okuyama, R, Stoolman, LM et al. (2005). Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern. Cancer Res 65:1063-1070. (Pubitemid 40216469)
19. Kaneko, S, Mastaglio, S, Bondanza, A, Ponzoni, M, Sanvito, F, Aldrighetti, L et al. (2009). IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive selfrenewing central memory human T lymphocytes. Blood 113:1006-1015.
20. Teague, RM, Sather, BD, Sacks, JA, Huang, MZ, Dossett, ML, Morimoto, J et al. (2006). Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat Med 12:335-341. (Pubitemid 43355083)
21. Liu, S, Riley, J, Rosenberg, S and Parkhurst, M (2006). Comparison of common gamma-chain cytokines, interleukin-2, interleukin-7, and interleukin-15 for the in vitro generation of human tumor-reactive T lymphocytes for adoptive cell transfer therapy. J Immunother 29:284-293. (Pubitemid 44297296)
22. Goodman, WA, Levine, AD, Massari, JV, Sugiyama, H, McCormick, TS and Cooper, KD (2009). IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol 183:3170-3176.
23. Korn, T, Mitsdoerffer, M, Croxford, AL, Awasthi, A, Dardalhon, VA, Galileos, G et al. (2008). IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci USA 105:18460-18465.
24. Quintarelli, C, Dotti, G, De Angelis, B, Hoyos, V, Mims, M, Luciano, L et al. (2008). Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood 112:1876-1885.
25. Foster, AE, Leen, AM, Lee, T, Okamura, T, Lu, A, Vera, J et al. (2007). Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12. J Immunother 30:506-516. (Pubitemid 46988084)
26. Kern, F, Faulhaber, N, Khatamzas, E, Frömmel, C, Ewert, R, Prösch, S et al. (1999). Measurement of anti-human cytomegalovirus T cell reactivity in transplant recipients and its potential clinical use: a mini-review. Intervirology 42:322-324. (Pubitemid 30122066)
27. Kannanganat, S, Ibegbu, C, Chennareddi, L, Robinson, HL and Amara, RR (2007). Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to singlecytokine-producing cells. J Virol 81:8468-8476. (Pubitemid 47242819)
28. Badr, G, Bédard, N, Abdel-Hakeem, MS, Trautmann, L, Willems, B, Villeneuve, JP et al. (2008). Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells. J Virol 82:10017-10031.
29. Proto-Siqueira, R, Figueiredo-Pontes, LL, Panepucci, RA, Garcia, AB, Rizzatti, EG, Nascimento, FM et al. (2006). PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma. Leuk Res 30:1333-1339. (Pubitemid 44307321)
30. Staege, MS, Banning-Eichenseer, U, Weissflog, G, Volkmer, I, Burdach, S, Richter, G et al. (2008). Gene expression profiles of Hodgkin's lymphoma cell lines with different sensitivity to cytotoxic drugs. Exp Hematol 36:886-896.
31. Cheever, MA, Allison, J P, Ferris, AS, Finn, OJ, Hastings, BM, Hecht, TT et al. (2009). The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15:5323-5337.
32. Andersen, MH, Svane, IM, Becker, JC and Straten, PT (2007). The universal character of the tumor-associated antigen survivin. Clin Cancer Res 13:5991-5994. (Pubitemid 350075053)
33. Otto, K, Andersen, MH, Eggert, A, Keikavoussi, P, Pedersen, LØ, Rath, JC et al. (2005). Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine 23:884-889. (Pubitemid 39643175)
34. Wobser, M, Keikavoussi, P, Kunzmann, V, Weininger, M, Andersen, MH and Becker, JC (2006). Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 55:1294-1298. (Pubitemid 43992055)
35. Meklat, F, Li, Z, Wang, Z, Zhang, Y, Zhang, J, Jewell, A et al. (2007). Cancer-testis antigens in haematological malignancies. Br J Haematol 136:769-776. (Pubitemid 46348406)
36. Quintarelli, C, Dotti, G, Hasan, ST, De Angelis, B, Hoyos, V, Errichiello, S et al. (2011). High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood 117:3353-3362.
37. Leisegang, M, Wilde, S, Spranger, S, Milosevic, S, Frankenberger, B, Uckert, W et al. (2010). MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. J Clin Invest 120:3869-3877.
38. Tassi, E, Braga, M, Longhi, R, Gavazzi, F, Parmiani, G, Di Carlo, V et al. (2009). Nonredundant role for IL-12 and IL-27 in modulating Th2 polarization of carcinoembryonic antigen specific CD4 T cells from pancreatic cancer patients. PLoS ONE 4:e7234.
39. Welters, MJ, Kenter, GG, Piersma, SJ, Vloon, A P, Löwik, MJ, Berends-van der Meer, DM et al. (2008). Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 14:178-187. (Pubitemid 351377994)
40. Melief, CJ and van der Burg, SH (2008). Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 8:351-360. (Pubitemid 351589701)
41. Goodyear, O, Agathanggelou, A, Novitzky-Basso, I, Siddique, S, McSkeane, T, Ryan, G et al. (2010). Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 116:1908-1918.
42. Gerdemann, U, Christin, AS, Vera, JF, Ramos, CA, Fujita, Y, Liu, H et al. (2009). Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther 17:1616-1625.
43. Yotnda, P, Onishi, H, Heslop, HE, Shayakhmetov, D, Lieber, A, Brenner, M et al. (2001). Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther 8:930-937. (Pubitemid 32600149)
44. Rossig, C, Bollard, CM, Nuchtern, JG, Rooney, CM and Brenner, MK (2002). Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 99:2009-2016. (Pubitemid 34525482)
45. Ayyoub, M, Merlo, A, Hesdorffer, CS, Speiser, D, Rimoldi, D, Cerottini, JC et al. (2005). Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2. Clin Immunol 114:70-78. (Pubitemid 39642792)
46. Ayyoub, M, Stevanovic, S, Sahin, U, Guillaume, P, Servis, C, Rimoldi, D et al. (2002). Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumorreactive CTL infiltrating metastatic melanoma. J Immunol 168:1717-1722. (Pubitemid 34135769)
47. Ayyoub, M, Hesdorffer, CS, Montes, M, Merlo, A, Speiser, D, Rimoldi, D et al. (2004). An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR. J Clin Invest 113:1225-1233. (Pubitemid 38544108)
48. Ayyoub, M, Hesdorffer, CS, Metthez, G, Stevanovic, S, Ritter, G, Chen, YT et al. (2004). Identification of an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cells. J Immunol 172:7206-7211. (Pubitemid 38669166)
49. Neumann, F, Wagner, C, Stevanovic, S, Kubuschok, B, Schormann, C, Mischo, A et al. (2004). Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2. Int J Cancer 112:661-668. (Pubitemid 39425947)